Form 4: Day One Biopharmaceuticals General Counsel Adam Dubow Reports Stock Transactions

Day One Biopharmaceuticals' General Counsel, Adam Dubow, reported the acquisition of shares through vesting of Restricted Stock Units (RSUs) and subsequent sale of some shares to cover tax liabilities.

Summary

• Adam Dubow, General Counsel of Day One Biopharmaceuticals, reported several transactions involving the company's common stock.
• On November 15, 2024, Dubow acquired a total of 8,400 shares through the vesting of Restricted Stock Units (RSUs).
• These RSUs vested in three tranches: 2,962, 1,750, and 3,687 shares.
• On November 18, 2024, Dubow sold 3,165 shares at a weighted average price of $13.2102 per share.
• The sale was solely to cover tax liabilities associated with the vesting of the RSUs.
• Following these transactions, Dubow directly owns 32,162 shares of Day One Biopharmaceuticals common stock.

Sentiment

Score: 7

Explanation: The document reflects routine insider transactions related to equity compensation. There is no indication of positive or negative sentiment, it is a standard filing.

Positives

• The vesting of RSUs indicates that the General Counsel is meeting the service requirements of the company.
• The sale of shares was explicitly for tax purposes, which is a common practice for executives receiving equity compensation.

Industry Context

This is a standard SEC Form 4 filing, which is common for company insiders who have stock transactions. It is a routine disclosure and does not indicate any unusual activity.

Comparison to Industry Standards

• The vesting of RSUs and subsequent sale of shares for tax purposes is a common practice among executives in publicly traded companies.
• The price range of $13.02 to $13.45 for the block trade is within a normal range for market fluctuations.
• Similar filings are regularly made by executives at comparable biotech companies such as BioMarin Pharmaceutical and Vertex Pharmaceuticals.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are routine and do not indicate any change in the company's fundamentals.
• The sale of shares by the General Counsel is a normal part of equity compensation and does not suggest any lack of confidence in the company.

Key Dates

Keywords

Form 4, insider trading, stock transaction, restricted stock units, RSU, Day One Biopharmaceuticals, Adam Dubow, equity compensation, tax liability